251 related articles for article (PubMed ID: 26600308)
1. Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Kannel K; Alnek K; Vahter L; Gross-Paju K; Uibo R; Kisand KV
PLoS One; 2015; 10(11):e0143393. PubMed ID: 26600308
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
[TBL] [Abstract][Full Text] [Related]
3. Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.
Wang S; Yang T; Wan J; Zhang Y; Fan Y
Brain Behav; 2017 Apr; 7(4):e00648. PubMed ID: 28413701
[TBL] [Abstract][Full Text] [Related]
4. Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients.
Mameli G; Cocco E; Frau J; Arru G; Caggiu E; Marrosu MG; Sechi LA
Sci Rep; 2016 Jul; 6():29268. PubMed ID: 27383531
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis.
Hamid KM; Nejati A; Shoja Z; Mollaei-Kandelousd Y; Doosti R; Mirshafiey A; Tafakhori A; Sahraian MA; Marashi SM
Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):75-81. PubMed ID: 26996115
[TBL] [Abstract][Full Text] [Related]
6. Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients.
Mameli G; Cossu D; Caggiu E; Arru G; Niegowska M; Cocco E; Frau J; Marrosu MG; Sechi LA
J Mol Neurosci; 2016 Sep; 60(1):91-3. PubMed ID: 27370541
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
8. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
9. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.
Ragheb S; Li Y; Simon K; VanHaerents S; Galimberti D; De Riz M; Fenoglio C; Scarpini E; Lisak R
Mult Scler; 2011 Jul; 17(7):819-29. PubMed ID: 21372118
[TBL] [Abstract][Full Text] [Related]
11. The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Damiano S; Sasso A; De Felice B; Terrazzano G; Bresciamorra V; Carotenuto A; Orefice NS; Orefice G; Vacca G; Belfiore A; Santillo M; Mondola P
Brain Res Bull; 2015 Sep; 118():1-6. PubMed ID: 26327496
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
Muls NG; Dang HA; Sindic CJ; van Pesch V
Mult Scler; 2015 Oct; 21(12):1533-45. PubMed ID: 25662347
[TBL] [Abstract][Full Text] [Related]
13. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.
Sternberg Z; Hennies C; Sternberg D; Bistulfi GL; Kazim L; Benedict RH; Chadha K; Leung C; Weinstock-Guttman B; Munschauer F
Mult Scler; 2011 Feb; 17(2):157-63. PubMed ID: 20965962
[TBL] [Abstract][Full Text] [Related]
14. Assessment of serum inflammatory parameters in RRMS and SPMS patients.
Nowak-Kiczmer M; Niedziela N; Czuba ZP; Sowa P; Wierzbicki K; Lubczyński M; Adamczyk-Sowa M
Neurol Res; 2024 Jun; 46(6):495-504. PubMed ID: 38697017
[TBL] [Abstract][Full Text] [Related]
15. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
Szczuciński A; Kalinowska A; Losy J
Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
[TBL] [Abstract][Full Text] [Related]
16. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
17. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.
Ragheb S; Lisak R; Lewis R; Van Stavern G; Gonzales F; Simon K
Arch Neurol; 2008 Oct; 65(10):1358-62. PubMed ID: 18852352
[TBL] [Abstract][Full Text] [Related]
18. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Lindquist S; Hassinger S; Lindquist JA; Sailer M
Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
[TBL] [Abstract][Full Text] [Related]
19. BAFF serum and CSF levels in patients with multiple sclerosis and infectious nervous system diseases.
Braun T; Juenemann M; Dornes K; El-Shazly J; Schramm P; Bick-Ackerschott S; Kaps M; Gerriets T; Blaes F; Tschernatsch M
Int J Neurosci; 2021 Dec; 131(12):1231-1236. PubMed ID: 32602764
[TBL] [Abstract][Full Text] [Related]
20. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
